LCAT-deficiency - from phenotype to genotype and beyond

It is 50 years since the first scientific articles about the lack of LCAT was published. The symposium will discuss the importance of what lecitihin-cholesterol acyltransferase (LCAT) means for the transport of cholesterol in the organism, and it will take place at the hospital where the hereditary disease LCAT deficiency was first discovered.

The meeting is open to all interested, but registration is needed


09:00 Welcome

Chairpersons: John Chapman, Bryan Brewer and Kaare R. Norum

LCAT patients and treatment

09:10 Kaare R. Norum

The Early History of LCAT and familial LCAT Deficiency

09:30 Helena Miettinen

Finnish patients with LCAT deficiency

09:50 Erik H. Strøm

Kidney Biopsies after Kidney Transplantation in a Norwegian Patient with familial LCAT Disease

Coffee break

10:20 Bruno E P Balbo and Carlos Sampaio

Brief history of LCAT deficiency in Hospital das Clínicas

10:50 Alan Remaley

Treatment of LCAT Deficiency Patients with recombinant LCAT

11:20 Ingrid Wiig

Norwegian National Advisory Unit on Rare Disorders.


LCAT Structure and Function

12:30 Jan Albert Kuivenhoven

LCAT and Atherosclerosis

13:00 Laura Calabresi

Genetic LCAT deficiency and atherosclerosis

13:30 John Tesmer

Structure and function of LCAT

14:00 Kelly Manthei

Studies on LCAT structure

14.15 Mingyue Zhou

LCAT Therapeutics Innovations


15:00 Sotirios Karathanasis

Acute LCAT infusion increase macrophage-specific cholesterol efflux in LCAT deficient human ApoA-1 transgenic mice

15:30 Dominic Ng

Non-Classical Metabolic Phenotypes of LCAT Deficiency – Lessons from Murine Models

16:00 Terje R. Pedersen

Future Pharmaceutical Agents for Treatment of Dyslipidemia

16:30 Rune Blomhoff

General discussion and closing remarks



The registration is now closed, and we can no longer offer lunch to new participants. The lectures are still open to all interested parties.


Published Mar. 22, 2017 10:49 AM - Last modified May 16, 2017 1:45 PM